ARC Medical, Inc.
Privately held medical device company developing high-molecular-weight, polymer-based liquid adhesion barrier medical devices intended to prevent or reduce internal surgical adhesions. The company conducts preclinical and clinical studies, operates ISO 13485:2016 and cGMP-aligned quality systems, holds a multi-family patent portfolio, and pursues partnerships and commercialization through clinical trials and investor engagement.
Industries
Nr. of Employees
small (1-50)
ARC Medical, Inc.
Unit 8 - 3071 No. 5 Road, Richmond, BC, Canada V6X 2T4
Patents
High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
US-11419891-B2
View DetailsPharmaceutical compositions comprising modified fucans and methods relating thereto
US-8466125-B2
View Details
High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
US-11419891-B2
View DetailsPharmaceutical compositions comprising modified fucans and methods relating thereto
US-8466125-B2
View DetailsProducts
JOCOAT
A high-molecular-weight polymer-based liquid adhesion barrier under clinical development for use in orthopedic surgeries (knee, shoulder, ankle, hip). Applied intraoperatively; flows through the joint and forms a temporary physical barrier film to mechanically separate tissues.
IPCOAT
A high-molecular-weight polymer-based liquid adhesion barrier under clinical development for gynecologic and abdominal surgeries. Applied intraoperatively into the abdominopelvic cavity where it flows and forms a temporary barrier film across tissues.
TENCOAT (in development)
Liquid adhesion barrier under development intended for tendon surgery applications.
VERCOAT (in development)
Liquid adhesion barrier under development intended for spine surgery applications.
JOCOAT
A high-molecular-weight polymer-based liquid adhesion barrier under clinical development for use in orthopedic surgeries (knee, shoulder, ankle, hip). Applied intraoperatively; flows through the joint and forms a temporary physical barrier film to mechanically separate tissues.
IPCOAT
A high-molecular-weight polymer-based liquid adhesion barrier under clinical development for gynecologic and abdominal surgeries. Applied intraoperatively into the abdominopelvic cavity where it flows and forms a temporary barrier film across tissues.
TENCOAT (in development)
Liquid adhesion barrier under development intended for tendon surgery applications.
VERCOAT (in development)
Liquid adhesion barrier under development intended for spine surgery applications.
Services
Strategic partnering, licensing and joint development agreements to advance device development, clinical trials, and commercialization.
Strategic partnering, licensing and joint development agreements to advance device development, clinical trials, and commercialization.
Expertise Areas
- Surgical adhesion prevention
- Clinical trial management (randomized, double-blind, safety and volume-escalation trials)
- Biocompatibility and GLP preclinical testing
- Polymer-based biomaterials for surgical use
Key Technologies
- High-molecular-weight polymer-based barrier fluids
- Liquid adhesion barrier forming temporary polymer film
- ISO 10993 biocompatibility testing
- GLP-compliant preclinical efficacy and mechanism studies
News & Updates
First clinical deployment of the fluid adhesion barrier in two surgical patients (knee and shoulder) following completion of a Phase 1 safety trial and supporting preclinical studies.
Secured USD $3 million to advance clinical trials for orthopedic and gynecological/abdominal indications and support partnership discussions.
Announcement that the liquid adhesion barrier had been used in 20 orthopedic surgery patients (16 knee, 4 shoulder) with early clinical observations of improved range of motion versus preoperative function.
Presentation of GLAD-01 randomized, controlled, double-blinded safety clinical trial (N=76) and supporting nonclinical efficacy and mechanism data; initiation of a clinical trial in gynecologic endometriosis patients announced.
Planned presentations and conference participation across 2024–2025 to engage partners, investors and clinicians and to present clinical and nonclinical data.
Company operates under an ISO 13485:2016 certified quality management system.
First clinical deployment of the fluid adhesion barrier in two surgical patients (knee and shoulder) following completion of a Phase 1 safety trial and supporting preclinical studies.
Secured USD $3 million to advance clinical trials for orthopedic and gynecological/abdominal indications and support partnership discussions.
Announcement that the liquid adhesion barrier had been used in 20 orthopedic surgery patients (16 knee, 4 shoulder) with early clinical observations of improved range of motion versus preoperative function.
Presentation of GLAD-01 randomized, controlled, double-blinded safety clinical trial (N=76) and supporting nonclinical efficacy and mechanism data; initiation of a clinical trial in gynecologic endometriosis patients announced.
Planned presentations and conference participation across 2024–2025 to engage partners, investors and clinicians and to present clinical and nonclinical data.
Company operates under an ISO 13485:2016 certified quality management system.